FDA Issues Final Guidance on Instructions for Use Documents

July 14, 2022

A woman holding instructions an a packet of pills.

The U.S. Food and Drug Administration has issued a final guidance, “Instructions for Use – Patient Labeling for Human Prescription Drug and Biological Products – Content and Format.”

The Instructions for Use (IFU) document is written for patients or their caregivers who use prescription drug and biological products that have complicated or detailed instructions. The recommendations in this guidance are intended to help provide consistency to the content and format of IFU documents and to help ensure that patients receive clear and concise information that is easily understood for the safe and effective use of such products.

This guidance finalizes the draft guidance that FDA issued in July 2019 titled “Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products — Content and Format, Guidance for Industry.” In the final guidance, FDA added clarifying language, consolidated discussions of human factors, and aligned the final guidance with the standards used in other Center for Drug Evaluation and Research policy documents.

This final guidance is a commitment included in the Prescription Drug User Fee Act (PDUFA) VI performance goals letter related to guidance on patient-oriented labeling (e.g., IFU documents).

Download the Final Guidance Document

Read the Federal Register Notice

Interested in learning more? Contact us today to find out how we can help with your global regulatory needs.


Alarm clock sitting on table.

July 25, 2022

FDA publishes two final guidances for industry: Orange Book Questions and Answers; Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe

July 2022 As part of FDA’s continued efforts to improve transparency and provide helpful information to regulated industry and the public, the agency is issuing two final guidances for generic drug...

July 26, 2016

FDA Warns Consumers of Hidden Drug Ingredients in Certain Xcelerated Weight Loss Products

On Friday, July 22nd , the FDA published three public notifications warning consumers of hidden drug ingredients that are present in various Xcelerated Weight Loss products. Two of the company’s...

March 22, 2022

FDA Issues Guidance on Certain Ophthalmic Products: Policy for Compliance with 21 CFR Part 4

The U.S. Food and Drug Administration today issued the guidance for industry, Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4. This guidance provides information to...